SuperGen (SUPG) Misses Q2 View By 2c
More News related to SUPG
- SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition
- SuperGen (SUPG) Receives Clearance to Begin Clinical Trials With SGI-1776
- SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
- SuperGen Appoints David Bearss, Ph.D., Chief Scientific Officer
- SuperGen to Present at the Fifth Annual Lazard Healthcare Conference on November 18, 2008
More News related to Earnings
- Citi Downgrades XenoPort (XNPT) to Hold, Slashes Price Target
- Analyst Previews Nokia's (NOK) Dec. 4 Analyst Day; Maintains Buy
- Wachovia Maintains an 'Outperform' Rating on Adobe (ADBE), Lowers Estimates
- Piper Jaffray Maintains a 'Buy' on Shanda Interactive (SNDA), Lowers Price Target
- Piper Jaffray Maintains a 'Neutral' on St. Jude Medical (STJ), Lowers Price Target and Earnings Estimates
SuperGen (Nasdaq: SUPG) reports a Q2 loss of $0.08, 2 cents lower than the analyst estimate of ($0.06). Revenues for the quarter were $8.1 million, versus the consensus of $8.71 million.
SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer.
Related Categories
EarningsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
